Avutometinib and Defactinib
Avutometinib and defactinib, when combined, are authorized for the treatment of adult patients diagnosed with recurrent, KRAS-mutated, low-grade serous ovarian cancer (LGSOC). This combination received accelerated approval from the FDA on May 8, 2025.
Mechanism of Action:
– Avutometinib targets the RAF/MEK/ERK signaling pathway, crucial for cell growth and proliferation, as a focused therapy.
– Defactinib, an oral FAK inhibitor, blocks the FAK protein linked to cancer cell growth and survival, also classified as a targeted therapy.
Clinical Trials:
In clinical trials, the combined therapy showed promising outcomes, particularly in patients with recurrent LGSOC who had KRAS mutations. The RAMP 201 study, a phase 2 registration-directed trial, assessed the effectiveness and safety of avutometinib alone and in conjunction with defactinib.
The results from the RAMP 201 trial validated the approval of this combined therapeutic approach.
Showing the single result
- - Mechanism of Action:
- - Clinical Trials:
Overview
Avutometinib and defactinib, when combined, are authorized for the treatment of adult patients diagnosed with recurrent, KRAS-mutated, low-grade serous ovarian cancer (LGSOC). This combination received accelerated approval from the FDA on May 8, 2025.
Mechanism of Action:
– Avutometinib targets the RAF/MEK/ERK signaling pathway, crucial for cell growth and proliferation, as a focused therapy.
– Defactinib, an oral FAK inhibitor, blocks the FAK protein linked to cancer cell growth and survival, also classified as a targeted therapy.
Clinical Trials:
In clinical trials, the combined therapy showed promising outcomes, particularly in patients with recurrent LGSOC who had KRAS mutations. The RAMP 201 study, a phase 2 registration-directed trial, assessed the effectiveness and safety of avutometinib alone and in conjunction with defactinib.
The results from the RAMP 201 trial validated the approval of this combined therapeutic approach.
Related Posts:
No matching posts found.